Navigation Links
BioDuro and AstraZeneca Expand Collaboration to Optimize Discovery Research for Respiratory and Inflammation Indications

BEIJING, March 23 /PRNewswire/ -- BioDuro and AstraZeneca announced today that they have expanded their research collaboration to optimize discovery research for Respiratory and Inflammation indications.

BioDuro will provide integrated research services in the areas of discovery chemistry, discovery biology, ADMET*, and DMPK** services, to help enhance internal drug discovery and shorten development timelines.

"After a successful collaboration involving discovery chemistry, ADMET, and DMPK, AstraZeneca has expanded its collaboration with BioDuro to leverage the strengths of its team to help develop new therapeutics," said Lena Martensson Director of Strategic Planning and Business Development.

"BioDuro is pleased to build upon this existing collaboration and work closely with the experienced team at AstraZeneca to develop new clinical compounds for Respiratory and Inflammation indications. This partnership demonstrates the strength of our innovation, quality, and our fully integrated R&D service platform," commented John Oyler, Chief Executive Officer and co-founder of BioDuro LLC.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of $31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. For more information about AstraZeneca, please visit:

About BioDuro

BioDuro is a US-based, fully-integrated, end-to-end global life science outsourcing services company with a team of 580 in Beijing, China. BioDuro combines western pharmaceutical company quality and professionalism, with entrepreneurial, innovative biotech culture, to leverage its talented, hard-working Chinese scientists. BioDuro's clients are over 40 pharmaceutical and biotechnology companies, including 10 of the top-12. BioDuro's services span the entire range of drug discovery and development, from discovery chemistry, discovery biology, early ADMET, DMPK, through pharmacology and drug safety and evaluation.

*ADMET: Absorption, Distribution, Metabolism, Excretion, and Toxicity

**DMPK: Drug Metabolism and Pharmacokinetics

Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioDuro & The National Center for Safety Evaluation of Drugs Received Full AAALAC Accreditation
2. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
3. AstraZeneca Implements Customized Cytel East(R) Software for More Accurate Trial Monitoring and Clinical Data Analysis
4. AstraZeneca Appoints Graham Baker Vice President and Chief Financial Officer for North America
5. AstraZeneca Nobel Medicine Initiative to Increase Interest in the Nobel Prize in Physiology or Medicine
6. AstraZeneca and M. D. Anderson Renew Cancer Research Collaboration
7. FDA Approves AstraZenecas SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
8. Melior Enters Research Collaboration with AstraZeneca
9. Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R)
10. AstraZeneca Survey: Healthcare Professionals Leading Source of Information on Companys Prescription Savings Programs
11. Weitz & Luxenberg Files Seroquel Diabetes Lawsuit Against AstraZeneca
Post Your Comments:
(Date:11/27/2015)... 2015 /PRNewswire/--  Mallinckrodt plc (NYSE: MNK ), ... has closed the sale of its global contrast media ... Euronext) in a transaction valued at approximately $270 million. ... a total of approximately 1,000 employees spread across the ... Louis area. This entire workforce and the ...
(Date:11/26/2015)... England , November 26, 2015 ... innovative medical device company specializing in imaging technologies, announced today ... European Commission as part of the Horizon 2020 European Union ... carry out a large-scale clinical trial in breast cancer. ... (Logo: , --> --> ...
(Date:11/25/2015)... 25, 2015 Studies reveal the ... plaque and pave the way for more effective treatment for ...     --> --> ... health problems in cats, yet relatively little was understood about ... studies have been conducted by researchers from the WALTHAM Centre ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... of Black Aerospace Professionals (OPBAP) has been formalized with the signing of a ... leaders met with OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn Tuesday, ...
Breaking Biology Technology:
(Date:10/29/2015)... 2015  Rubicon Genomics, Inc., today announced an ... its DNA library preparation products, including the ThruPLEX ... Plasma-seq kit. ThruPLEX Plasma-seq has been optimized for ... libraries for liquid biopsies--the analysis of cell-free circulating ... in cancer and other conditions. Eurofins Scientific is ...
(Date:10/27/2015)... Munich, Germany , ... (ASGM) automatically maps data from mobile eye tracking videos ... so that they can be quantitatively analyzed with SMI,s ... Germany , October 28-29, 2015. SMI,s Automated Semantic ... eye tracking videos created with SMI,s Eye Tracking ...
(Date:10/23/2015)... Research and Markets ( ) has announced the ... 2015-2019" report to their offering. ... recognition biometrics market to grow at a CAGR of ... --> The report, Global Voice Recognition Biometrics ... market analysis with inputs from industry experts. The report ...
Breaking Biology News(10 mins):